查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1446461

流感诊断市场规模、份额、趋势分析报告：按测试类型、最终用途、地区、细分市场预测，2024-2030 年

Influenza Diagnostics Market Size, Share & Trends Analysis Report By Test Type (RIDT, RT-PCR, Cell Culture), By End-use (Hospitals, POCT, Laboratories), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

流感诊断市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球流感诊断市场规模将达到24.1亿美元，2024年至2030年复合年增长率为5.78%。

感染监测的加强和全球慢性病盛行率的上升增加了对流感诊断的需求。例如，2022年9月，102个国家的国家流感中心和其他实验室在2022年8月22日至2022年9月4日期间检测了超过112,017份检体。其中，3,879 个检体被确定为流感病毒阳性。

包括世界卫生组织和美国卫生与公众服务部在内的国际组织和法规正在加强遏制疾病的传播。这些组织从事流感疫苗的综合研究和开发。多家公司已被证实正在开发以细胞培养为基础的疫苗，包括 VIDRL、Sequirus 和 CDC。因此，这项策略倡议可能会透过增加对细胞培养技术的需求对市场产生正面影响。

例如，2022年9月，世卫组织使用经过认证的含有NIID-MDCK的细胞株来分离人类流感病毒。该组织还对基于细胞培养的疫苗候选病毒进行了遗传和抗原分析。此候选疫苗已通过针对细胞培养原型病毒的双向病毒中和测试或血凝抑制测试，符合世界卫生组织的建议。细胞培养候选疫苗预计将于 2023 年准备开发和生产。

在 COVID-19 大流行期间，监测和检测流感病毒的监测急剧减少。同样，从 10 月到 4 月，与流感相关的住院治疗也出现了趋势。例如，从 2019 年 10 月到 2020 年 4 月，美国报告了约 19,299 例住院病例，而 2020-21 年同期仅报告了 232 例，因此在 COVID-19 高峰期间，这意味着病例减少了大约98 %。然而，世卫组织建议各国为 COVID-19 和流感病毒的同时爆发做好准备。这鼓励地方法规整合监测计画并加强流感疫苗接种宣传活动。

POCT（即时检测）在包括流感在内的感染疾病快速诊断领域的日益普及，预计将增加开发中国家对流感诊断的需求。例如，2022 年 10 月进行了一项研究，评估欧洲国家感染疾病的 POCT 覆盖率。根据这项研究，在监测下，POCT广泛用于高发病率的感染疾病，如爱滋病毒和流感。

流感诊断市场报告亮点

  • 按测试类型划分，快速流感诊断测试 (RIDT) 领域处于市场领先地位，占 2023 年全球销售额的 30.88%，预计在预测期内将呈现最快的复合年增长率。上市公司不断推出的产品开发和新兴市场使用等策略性倡议正在推动市场成长。
  • 按最终用途划分，2023 年医院将占据最大的市场收益占有率。这是由于气喘和其他慢性健康状况等潜在健康状况的日益增多，增加了流感併发症的风险。
  • 北美市场占据主导地位，2023年占总市占率的32.69%。这是由于企业更多地获取流感负担资料以及该地区监测测试的增加。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章流感诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 流感诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 价格分析

第四章流感诊断市场：检测类型的估计和趋势分析

  • 2023 年和 2030 年测试类型市场占有率
  • 细分仪表板
  • 按测试类型分類的全球流感诊断市场展望
  • 2018年至2030年市场规模、预测与趋势分析
    • RIDT
    • RT-PCR
    • 细胞培养
    • 其他的

第五章流感诊断市场：最终用途估计与趋势分析

  • 2023 年及 2030 年最终用途市场占有率
  • 细分仪表板
  • 按最终用途分類的全球流感诊断市场展望
  • 2018年至2030年市场规模、预测与趋势分析
    • 医院
    • POCT
    • 研究机构

第六章流感诊断市场：按地区估计和趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模及预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • 3M Company
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • Meridian Bioscience, Inc.
    • Quidel Corporation.
    • F. Hoffmann-La Roche Ltd.
    • SA Scientific Ltd
    • SEKISUI Diagnostics
    • Thermo Fisher Scientific, Inc.
    • Hologic, Inc.
Product Code: GVR-1-68038-259-4

Influenza Diagnostics Market Growth & Trends:

The global influenza diagnostics market size is expected to reach USD 2.41 billion by 2030, registering a CAGR of 5.78% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing surveillance of the infection and the rising prevalence of chronic diseases around the world are contributing to the demand for influenza diagnostics. For instance, in September 2022, National Influenza Centres and other laboratories from 102 countries tested over 112,017 specimens between 22 August 2022 to 04 September 2022. Out of those, 3,879 tested positive for influenza viruses.

The increasing involvement of international organizations and regulations, such as WHO and the U.S. Department of Health & Human Services to control the spread of infection. The organizations are indulging in comprehensive research and development of a vaccine for influenza. It has been observed that various companies such as VIDRL, Seqirus, and CDC are developing cell culture-based vaccines. Thus, this strategic initiative is likely to have a positive impact on the market through increasing demand for cell culture technology.

For instance, in September 2022, WHO used a certified cell line including NIID-MDCK for isolating the human influenza virus. The organization also performed genetic and antigenic analysis on the cell culture-based candidate vaccine viruses. The vaccine candidates have passed two-way virus neutralization tests or hemagglutination inhibition against the cell culture prototype viruses and match the recommendation by WHO. It is anticipated that cell-culture-derived vaccine candidates will be available for development and production in 2023.

During the COVID-19 pandemic, the surveillance to monitor and detect the influenza virus drastically decreased. Similarly, the trend was witnessed in flu-related hospitalization cases between October to April. For instance, from October 2019 to April 2020, approximately 19,299 cases of hospitalization were reported in the U.S. While in the same months in 2020-21, only 232 cases were reported, hence, approximately 98% fall in the cases during the peak of COVID-19. However, WHO recommended countries be ready for the co-circulation of COVID-19 and influenza viruses. This encourages the regional regulations to integrate the surveillance program and step-up vaccination campaigns for flu.

The growing availability of point-of-care testing (POCT) in the area of rapid diagnostics of infectious diseases including flu, is expected to increase the demand for influenza diagnostics in developing countries. For instance, a study was conducted in October 2022, to assess the POCT scope for infectious diseases in European countries. As per the study, under surveillance, POCT is widely used for infectious diseases with significant incidence rates, such as HIV and flu.

Moreover, at the global level, flu activity is considerably low. As per the September 2022 report by WHO, the South African region has witnessed a significant rise in flu activity in the past few weeks, and majorly with influenza B viruses were reported. However, in regions such as Central Asia and Northern Africa, no detection of flu was reported. Decreasing incidence rates is anticipated to impact the growth of the market through low product development by companies.

Influenza Diagnostics Market Report Highlights:

  • By test type, Rapid influenza diagnostics tests (RIDTs) segment led the market and accounted for 30.88% of the global revenue in 2023 and is expected to exhibit the fastest CAGR over the forecast period. Owing to the increasing strategic initiatives such as product development and expanding the scope of usage to public events by the companies, hence, driving the market growth
  • By end-user, the hospitals accounted for largest market revenue share in 2023. This is attributed to the growing presence of underlying medical conditions such as asthma and other chronic health conditions, which increases the risk of flu complications
  • North America dominated the market and accounted for a 32.69% share in 2023 of the overall market share. Owing to the increasing accessibility of data on the influenza burden to the companies, and rising surveillance testing in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Type
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Type outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Influenza Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising geriatric population
      • 3.2.1.2. Increasing prevalence of diseases
      • 3.2.1.3. Government initiatives to counter influenza
      • 3.2.1.4. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Product safety and high development cost
  • 3.3. Influenza Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. Influenza Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Influenza Diagnostics Market by Test Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. RIDT
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. RT-PCR
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Cell Culture
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Influenza Diagnostics Market: End-Use Estimates & Trend Analysis

  • 5.1. End-Use Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Influenza Diagnostics Market by End Use Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hospitals
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 5.4.2. POCT
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Laboratories
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Influenza Diagnostics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2023 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Mexico
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Argentina
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/ reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2023
    • 7.3.4. 3M Company
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Abbott Laboratories
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Becton, Dickinson and Company
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Meridian Bioscience, Inc.
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Quidel Corporation.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. F. Hoffmann-La Roche Ltd.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. SA Scientific Ltd
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. SEKISUI Diagnostics
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Thermo Fisher Scientific, Inc.
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Hologic, Inc.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 4 North America influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 6 U.S. influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 8 Canada influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Europe influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 10 Europe influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 11 Europe influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Germany influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 13 Germany influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 14 UK influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 15 UK influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 16 France influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 17 France influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Italy influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 19 Italy influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Spain influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 21 Spain influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Denmark influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 23 Denmark influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Sweden influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 25 Sweden influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Norway influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 27 Norway influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 31 China influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 32 China influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 33 Japan influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 34 Japan influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 35 India influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 36 India influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 37 South Korea influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 38 South Korea influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 39 Australia influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 40 Australia influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Thailand influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 42 Thailand influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Latin America influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 45 Latin America influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 46 Brazil influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 47 Brazil influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Mexico influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 49 Mexico influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Argentina influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 51 Argentina influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 52 MEA influenza diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 53 MEA influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 54 MEA influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 55 South Africa influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 56 South Africa influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 59 UAE influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 60 UAE influenza diagnostics market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 62 Kuwait influenza diagnostics market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Influenza diagnostics market: market outlook
  • Fig. 14 Influenza diagnostics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Influenza diagnostics market driver impact
  • Fig. 20 Influenza diagnostics market restraint impact
  • Fig. 21 Influenza diagnostics market strategic initiatives analysis
  • Fig. 22 Influenza diagnostics market: Test Type movement analysis
  • Fig. 23 Influenza diagnostics market: Test Type outlook and key takeaways
  • Fig. 24 RIDT market estimates and forecast, 2018 - 2030
  • Fig. 25 RT-PCR estimates and forecast, 2018 - 2030
  • Fig. 26 Cell Culture market estimates and forecast, 2018 - 2030
  • Fig. 27 Others estimates and forecast, 2018 - 2030
  • Fig. 28 Influenza diagnostics Market: End Use movement Analysis
  • Fig. 29 Influenza diagnostics market: End use movement analysis
  • Fig. 30 Influenza diagnostics market: End use outlook and key takeaways
  • Fig. 31 Hospitals market estimates and forecasts, 2018 - 2030
  • Fig. 32 POCT market estimates and forecasts,2018 - 2030
  • Fig. 33 Laboratories market estimates and forecasts,2018 - 2030
  • Fig. 34 Global influenza diagnostics market: Regional movement analysis
  • Fig. 35 Global influenza diagnostics market: Regional outlook and key takeaways
  • Fig. 36 Global influenza diagnostics market share and leading players
  • Fig. 37 North America market share and leading players
  • Fig. 38 Europe market share and leading players
  • Fig. 39 Asia Pacific market share and leading players
  • Fig. 40 Latin America market share and leading players
  • Fig. 41 Middle East & Africa market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030
  • Fig. 44 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 46 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 47 UK market estimates and forecasts, 2018 - 2030
  • Fig. 48 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 49 France market estimates and forecasts, 2018 - 2030
  • Fig. 50 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 51 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 52 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 53 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 54 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 55 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 56 China market estimates and forecasts, 2018 - 2030
  • Fig. 57 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 58 India market estimates and forecasts, 2018 - 2030
  • Fig. 59 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 60 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 61 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 62 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 63 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 64 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 65 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 66 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 67 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 68 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 69 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 70 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 71 Market share of key market players- influenza diagnostics market